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HIV is largely resistant to complement-mediated lysis pri-
marily due to binding of factor H from the fluid phase and
secondarily to incorporation of additional complement
control proteins (DAF, MCP, CD59) from the host cell
into the viral envelope. Since HIV by itself activates the
complement system – and even more so, if antibodies are
bound to its surface, fragments of C3, i.e. C3b – are depos-
ited on the virus. We could document this situation for
exvivo HIV, isolated from human plasma.
Depending on the quantity of activation this may reach
such a degree that gp120 is not accessible any more. It
could be clearly shown that HIV carrying C3b binds to
complement receptor typ 1 (CR1) on human erytrocytes
(E). Thereby, with the help of the C3b inactivator, C3b is
converted into iC3b and further to C3d. HIV-iC3b/HIV-
C3d bind to B lymphocytes (CR2, CR1), to FDCs (CR2,
CR3, CR1) and to DCs (CR3).
HIV-C3d/B cell- and HIV-C3d/FDC – complexes very effi-
ciently infect resting (!) CD4+ T lymphocytes. HIV-iC3b,
bound to DCs, causes a productive (!) infection of these
cells! HIV – IgG or HIV-IgG-iC3b allows only attachment
of HIV to DCs. In both cases HIV can be transmitted to T
cells and productively infect these cells.
These complement-mediated infection enhancement
mechanisms can be overcome by sufficient large quanti-
ties of broadly neutralising antibodies.
But if these drop to low concentrations, then the fact that
these antibodies activate complement and cause opsoni-
sation of HIV with C3 fragments becomes the salient fea-
ture and the before neutralising antibodies begin to
enhance infection.
In our judgment, this complement-deposition by anti-
bodies to surface epitopes is one of the aspects, which
make development of a vaccine so difficult.
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